O
ONKURE THERAPEUTICS, INC.
NASDAQ: OKUR (OnKure Therapeutics, Inc.)
Last update: 2 hours ago2.62
0.00 (0.00%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | OnKure Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.8 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.92 |
Select this tab to load the latest available analysis.
|
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.57% |
| % Held by Institutions | 98.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ra Capital Management, L.P. | 30 Jun 2026 | 3,998,333 |
| Acorn Capital Advisors, Llc | 30 Jun 2026 | 2,839,674 |
| Stepstone Group Lp | 30 Jun 2026 | 2,660,612 |
| Adar1 Capital Management, Llc | 30 Jun 2026 | 2,238,684 |
| Vivo Capital, Llc | 30 Jun 2026 | 1,927,710 |
| Vestal Point Capital, Lp | 30 Jun 2026 | 1,825,699 |
| Trails Edge Capital Partners, Lp | 30 Jun 2026 | 1,438,456 |
| Sio Capital Management, Llc | 30 Jun 2026 | 1,078,965 |
| Prosight Management, Lp | 30 Jun 2026 | 978,992 |
| Logos Global Management Lp | 30 Jun 2026 | 963,855 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |